The hon. Lady tempts me, but I will resist the temptation. We do not know when this vaccine will be ready, because I will not allow it to be rolled out before it is clinically safe—and anyway, the independent regulator would not license it before it is clinically safe. She asked how we will treat people who have been vaccinated and those who have not been. The problem is that only when we can assess and monitor the epidemic-modifying effects of any vaccine—not only how much it protects an individual but how much it stops transmission—can we make further judgments about the non-pharmaceutical interventions, such as social distancing rules, that we have in place. We will keep that under review and monitor it extremely carefully.